{{Rsnum
|rsid=2284017
|Gene=CACNG2
|Chromosome=22
|position=36700882
|Orientation=plus
|GMAF=0.4449
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=CACNG2
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 29.2 | 56.6 | 14.2
| HCB | 29.2 | 46.7 | 24.1
| JPT | 24.8 | 49.6 | 25.7
| YRI | 2.7 | 29.3 | 68.0
| ASW | 5.3 | 47.4 | 47.4
| CHB | 29.2 | 46.7 | 24.1
| CHD | 26.6 | 50.5 | 22.9
| GIH | 27.7 | 44.6 | 27.7
| LWK | 4.5 | 32.7 | 62.7
| MEX | 22.8 | 43.9 | 33.3
| MKK | 14.7 | 47.4 | 37.8
| TSI | 28.4 | 54.9 | 16.7
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs2284017
|Name_s=
|Gene_s=CACNG2
|Feature=
|Evidence=PubMed ID:18408563
|Annotation=The C allele of this variant is associated with increased response of patients with bipolar disorder to lithium treatment relative to that observed in patients carrying two copies of the T allele. This association was observed in two separate cohorts: one of 188 patients, and one of 151 patients.
|Drugs=lithium
|Drug Classes=
|Diseases=Bipolar Disorder
|Curation Level=Curated
|PharmGKB Accession ID=PA161659504
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2284017
|overall_frequency_n=57
|overall_frequency_d=128
|overall_frequency=0.445312
|n_genomes=36
|n_genomes_annotated=0
|n_haplomes=47
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | Illumina Human 1M}}